When Nicole Smith-Holt’s 26-year-old son died, he had just moved out of his parents’ home and was starting a life of his own.
Sandoz on Wednesday announced an agreement with Gan & Lee Pharmaceuticals to commercialize biosimilar versions of insulins used to treat patients with type 1 and type 2 diabetes.
Christopher Noble is one of 7 million Americans who need insulin to manage their diabetes.
More than 7-million Americans need insulin to live. But insulin prices have nearly tripled since 2002, causing some patients to go to extreme lengths to afford their medication.
Nearly one in 10 Americans has diabetes. But because of rising insulin prices many of them struggle to afford the drugs they need and some diabetics ration their dosage.
Insulin use is expected to rise 20 percent by 2030, and many people who need it for Type 2 diabetes won’t have access, a study from Stanford University suggests.
More than 400,000 individuals have signed the ADA’s Make Insulin Affordable petition, as the ADA marks second anniversary of the initiative.
“Perverse” incentives in the insulin supply chain lead to artificially high prices, as well as limited competition in the markets, according to a bipartisan report released Thursday by two lawmakers.
Insulin in the United States isn’t free — in fact, it’s remarkably expensive, with some of today’s newest varieties costing over $500 for a box of five pens, according to GoodRx.
After years of rising insulin prices, a growing number of diabetics and their families are now facing some tough choices when it comes to paying for the drug.
Insurance companies commonly switch up which brand of medication is considered their preferred option. Before the plan will pay for a more expensive brand, patients must prove the lower-cost option doesn’t work for them.
26-year-old Alec Smith couldn’t afford the $1,300 a month insulin he needed to control his diabetes, so he tried rationing it — and died. His mother is now speaking out, telling NBC News she lost her son “because of pharmaceutical greed.” Read more here.